Literature DB >> 11435982

Human monocytic ehrlichiosis: an emerging pathogen in transplantation.

H P Tan1, J S Dumler, W R Maley, A S Klein, J F Burdick, F Fred Poordad, P J Thuluvath, J S Markowitz.   

Abstract

BACKGROUND: The spectrum of disease caused by Ehrlichia spp. ranges from asymptomatic to fatal. Awareness and early diagnosis of the infection is paramount because appropriate therapy leads to rapid defervescence and cure. If left untreated, particularly in immunosuppressed patients, ehrlichioses may result in multi-system organ failure and death.
METHODS: We report the second case of human monocytic ehrlichiosis (HME) in a liver transplant recipient, and review the literature.
RESULTS: The patient presented with fever and headache, had negative cultures, and despite broad-spectrum antimicrobial coverage appeared progressively septic. After eliciting a history of tick exposure we treated the patient empirically with doxycycline. The diagnosis of HME was confirmed by 1) polymerase chain reaction (PCR) for Ehrlichia chaffeensis, 2) acute and convalescent serum titers, and 3) in vitro cultivation of E chaffeensis from peripheral blood.
CONCLUSION: Although human ehrlichioses are relatively uncommon, they are emerging as clinically significant arthropod-borne infections. Although epidemiological exposure is responsible for infection, immunosuppression makes patients more likely to succumb to disease. A high index of suspicion and early treatment results in a favorable outcome.

Entities:  

Mesh:

Year:  2001        PMID: 11435982     DOI: 10.1097/00007890-200106150-00030

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Increasing incidence of Ehrlichia chaffeensis and Anaplasma phagocytophilum in the United States, 2000-2007.

Authors:  F Scott Dahlgren; Eric J Mandel; John W Krebs; Robert F Massung; Jennifer H McQuiston
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

2.  Increasing Incidence of Ehrlichiosis in the United States: A Summary of National Surveillance of Ehrlichia chaffeensis and Ehrlichia ewingii Infections in the United States, 2008-2012.

Authors:  Kristen Nichols Heitman; F Scott Dahlgren; Naomi A Drexler; Robert F Massung; Casey Barton Behravesh
Journal:  Am J Trop Med Hyg       Date:  2015-11-30       Impact factor: 2.345

3.  First case of human "Candidatus Neoehrlichia mikurensis" infection in a febrile patient with chronic lymphocytic leukemia.

Authors:  Christina Welinder-Olsson; Eva Kjellin; Krista Vaht; Stefan Jacobsson; Christine Wennerås
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

Review 4.  Human ehrlichiosis and anaplasmosis.

Authors:  Nahed Ismail; Karen C Bloch; Jere W McBride
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

Review 5.  Severe Ehrlichia chaffeensis infection in a lung transplant recipient: a review of ehrlichiosis in the immunocompromised patient.

Authors:  Nasia Safdar; Robert B Love; Dennis G Maki
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

Review 6.  Ehrlichia chaffeensis: a prototypical emerging pathogen.

Authors:  Christopher D Paddock; James E Childs
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

7.  Ehrlichia infection of the central nervous system.

Authors:  Igen Hongo; Karen C Bloch
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.972

8.  Myocarditis after trimethoprim/sulfamethoxazole treatment for ehrlichiosis.

Authors:  Seema U Nayak; Gary L Simon
Journal:  Emerg Infect Dis       Date:  2013-12       Impact factor: 6.883

9.  Assessment of Risk Factors and Outcomes of Severe Ehrlichiosis Infection.

Authors:  Kevin Kuriakose; April C Pettit; Jonathan Schmitz; Abelardo Moncayo; Karen C Bloch
Journal:  JAMA Netw Open       Date:  2020-11-02

Review 10.  The Impact of Tick-Borne Diseases on the Bone.

Authors:  Imran Farooq; Tara J Moriarty
Journal:  Microorganisms       Date:  2021-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.